Clinical efficacy and safety of Tulosin (tamsulosin) in patients with benign prostatic hyperplasia
31999
The author presented results of the clinical study on efficacy and safety of alpha1-adrenoreceptor antagonist Tulosin (produced by «Egis») as a single agent therapy in patients with benign prostatic hyperplasia (BPH). The research team included 30 patients aged 50 to 82 years. Inclusion criteria – patients with BPH, expressiveness symptoms on a scale International Prostate Symptom Score (IPSS) more 9 points, the volume of residual urine not more than 100 ml. Treatment was conducted within 2 months, with compulsory monitoring of patient every month.
- Read more about Clinical efficacy and safety of Tulosin (tamsulosin) in patients with benign prostatic hyperplasia
- Log in or register to post comments
- 31999 views
